Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lannett, Amneal Enter Levothyroxine Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lannett, Amneal Enter Levothyroxine Pact

Lannett will receive $50 million upfront

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lannett Company, Inc. has entered into an agreement with Amneal Pharmaceuticals, Inc. with regard to Levothyroxine Sodium Tablets USP. Amneal will be Lannett’s sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers. Lannett will receive $50 million upfront, other terms of the transaction were not disclosed.

“This agreement benefits all parties, including and importantly patients and customers who can be assured of a definitive transition and supply plan for this important medication,” said Tim Crew, chief executive officer of Lannett.  “For Lannett, this transaction guarantees $50 million of gross profit, which exceeded our previous projections for the 16 week period.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters